THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements ("Agreement") and/or amendments to Agreements ("Amendments") fall under the State of Michigan Conflict of Interest Statute because University of Michigan ("University") employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents ("Regents") of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator's effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

Arthur Lupia
Interim Vice President for Research and Innovation

July 2024

Attachment A

Project #1

Research Agreement between the University and Amphionic LLC **Reviewed by the UMOR Conflict of Interest Review Committee**	
Project Information	
Title: Design of Nanostructural Composites for Radiation Shielding	**U-M Project ID:** 24-PAF06649
Direct Sponsor: Amphionic LLC	
Principal Investigator/Department: Nicholas Kotov, Chemical Engineering	
Project Duration: One (1) Year	**Funding Support:** $126,000
Purpose: The purpose of this project is to provide the groundwork for a variety of mechanically robust, high-performance, radiation shielding platforms, with possible expansion into light-weight radiation detection applications and in high flexure or ruggedized environments.	
University Employee; University Title; Relationship with Amphionic LLC ● Mark Hammig; Research Scientist, Nuclear Engineering and Radiological Sciences; Partial Owner ● Suneel Joglekar; Research Fellow, Nuclear Engineering and Radiological Sciences; CEO ● Drew Vecchio; Research Fellow, Nuclear Engineering and Radiological Sciences; Vice President of Engineered Materials	

Project #2

SBIR Phase II Subcontract Agreement between the University and Arbor Batteries, Inc. (formerly known as Arbor Batteries LLC) **Reviewed by the UMOR Conflict of Interest Review Committee**	
Project Information	
Title: Li-ion Batteries with 3-D Structured Anodes to Minimize Inactive Materials and Improve Safety	**U-M Project ID:** 24-PAF06954
Direct Sponsor: Arbor Batteries, Inc.	**Prime Sponsor:** Department of Energy
Principal Investigator/Department: Neil Dasgupta, Mechanical Engineering	
Project Duration: Two (2) Years	**Funding Support:** $80,000
Purpose: The purpose of this project is to advance a laser ablation technique to 3D-structure thick graphite and graphite/silicon blend electrodes for lithium-ion batteries.	
University Employee; University Title; Relationship with Arbor Batteries, Inc. ● Neil Dasgupta; Associate Professor, Mechanical Engineering; Partial Owner	

Project #3

Clinical Trial Site Activity Agreement between the University and Ascentage Pharma Group Inc. Reviewed by the Medical School Conflict of Interest Board	
Project Information	
Title: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	**U-M Project ID:** 24-PAF06586
Direct Sponsor: Ascentage Pharma Group Inc.	
Principal Investigator/Department: Sami Malek, Hematology/Oncology	
Project Duration: Eight (8) Years	**Funding Support:** $2,135,240
Purpose: The purpose of this activity is to evaluate the progression-free survival (PFS) of lisaftoclax in combination with acalabrutinib compared with acalabrutinib monotherapy in CLL/SLL patients previously treated with acalabrutinib, as determined by independent radiological review committee (IRC) using the iwCLL guidelines.	
University Employee; University Title; Relationship with Ascentage Pharma Group Inc. ● Shaomeng Wang; Professor, Hematology/Oncology; Partial Owner	

Project #4

SBIR Phase I/II Subcontract Agreement between the University and Blue Arbor Technologies, Inc. Reviewed by the Medical School Conflict of Interest Board	
Project Information	
Title: Development and Clinical Testing of an Advanced Neuroprosthetic Control System	**U-M Project ID:** 24-PAF07752
Direct Sponsor: Blue Arbor Technologies, Inc.	**Prime Sponsor:** National Institutes of Health
Principal Investigator/Department: Deanna Gates, Kinesiology	
Project Duration: Five (5) Years	**Funding Support:** $1,892,088
Purpose: The purpose of this project is to develop and test implantable devices for high fidelity prosthetic hand control and to obtain the necessary IRB and FDA approvals to conduct take-home trials with the wearable device at the University of Michigan. The next phase will perform implant surgeries at the University of Michigan and manage surgical care of the clinical trial participants.	
University Employee; University Title; Relationship with Blue Arbor Technologies, Inc. ● Alex Vaskov; Research Fellow, Plastic Surgery; Partial Owner ● Paul Cederna; Professor, Plastic Surgery; Partial Owner ● Theodore Kung; Associate Professor, Surgery; Partial Owner	

Project #5

Clinical Trial Site Activity Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board	
Project Information	
Title: SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression	**U-M Project ID:** 24-PAF05425
Direct Sponsor: Eli Lilly and Company	
Principal Investigator/Department: Angel Qin, Hematology/Oncology	
Project Duration: Five (5) Years	**Funding Support:** $537,819
Purpose: The purpose of this activity is to compare LY3537982 in combination with pembrolizumab to placebo in combination with pembrolizumab as first-line treatment for participants with a tumor with PD-L1 expression =50% (Part A), and to compare LY3537982 in combination with pembrolizumab plus pemetrexed and platinum to placebo in combination with pembrolizumab plus pemetrexed and platinum as firstline treatment of participants with a tumor with PD-L1 expression 0 to 100% (Part B) in a global, multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial that will enroll participants with unresectable, advanced or metastatic KRAS G12C-mutant NSCLC.	
University Employee; University Title; Relationship with Eli Lilly and Company ● Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member	

Project #6

Amendment to Research Agreement between the University and iReprogram, Inc. Reviewed by the Medical School Conflict of Interest Board	
Project Information	
Title: iReprogram's Partnership with the University of Michigan (Rajapakse Lab) - (continuation + additional funding)	**U-M Project ID:** 24-PAF08114
Direct Sponsor: iReprogram, Inc.	
Principal Investigator/Department: Indika Rajapakse, Computational Medicine and Bioinformatics	
Agreement Initially Approved by the Regents: September 21, 2023	
Current Project Duration: Thirteen (13) Months **Additional Time:** Eighteen (18) Months	**Current Funding Support:** $157,042 **Additional Funding Support:** $1,187,831
Purpose: The purpose of this amendment is to add time and funds so that Dr. Rajapakse may continue to: 1) refine the Data Guided Control (DGC) algorithm with new data from primary hematopoietic stem cells (HSC), primary chondrocytes, and primary cardiofibroblasts, 2) select transcription factor (TF) reprogramming recipes and perform direct reprogramming of fibroblasts to the target cell types: iHSCs, iChondrocytes, and iCardiofibroblasts, 3) collect population and single cell RNAseq transcriptomes during reprogramming, and 4) use the collected transcriptomes to further refine the DGC algorithm.	
University Employee; University Title; Relationship with iReprogram, Inc. ● Lindsey Muir; Research Assistant Professor, Computational Medicine and Bioinformatics; Partial Owner ● Indika Rajapakse; Associate Professor, Computational Medicine and Bioinformatics; Partial Owner ● Gil Omenn; Professor, Computational Medicine and Bioinformatics; Board of Directors Member	

Project #7

Research Agreement between the University and NS Nanotech Inc. **Reviewed by the UMOR Conflict of Interest Review Committee**	
Project Information	
Title: Improve the Performance of InGaN Nanowire Red Micro-LEDs	**U-M Project ID:** 24-PAF08305
Direct Sponsor: NS Nanotech Inc.	
Principal Investigator/Department: Zetian Mi, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS – ECE) Division	
Project Duration: Six (6) Months	**Funding Support:** $150,000
Purpose: The purpose of this project is to perform a detailed study of the epitaxial growth and characterization of InGaN nanowire red-emitting LED heterostructures, identify the major contributors for the large spectral broadening and efficiency droop, and further develop innovative solutions to potentially mitigate these challenges.	
University Employee; University Title; Relationship with NS Nanotech Inc. ● Zetian Mi; Professor, EECS – ECE Division; Partial Owner	

Project #8

Fourth Amendment to Other Sponsored Activity Agreement between the University and Rappta Therapeutics Oy **Reviewed by the Medical School Conflict of Interest Board**	
Project Information	
Title: Characterizing role of novel PP2A activators in human cancer	**U-M Project ID:** 24-PAF07832
Direct Sponsor: Rappta Therapeutics Oy	
Principal Investigator/Department: Goutham Narla, Internal Medicine – Genetic Medicine	
Agreement Originally Approved by the Regents: October 21, 2021 **First Amendment Approved by the Regents:** July 21, 2022 **Second Amendment Approved by the Regents:** March 23, 2023 **Third Amendment Approved by the Regents:** February 15, 2024	
Current Project Duration: Four (4) Years, Four (4) Months	**Current Funding Support:** $3,400,000 **Additional Funding Support:** $1,200,000
Purpose: The purpose of this amendment is to add additional funds so that Dr. Narla may continue to test the effects of a series of small molecule activators of PP2A on a series of cancer cell lines.	
University Employee; University Title; Relationship with Rappta Therapeutics Oy ● Goutham Narla; Professor, Internal Medicine – Genetic Medicine; Partial Owner	

Project #9

STTR Phase I Subcontract Agreement between the University and Rydberg Technologies Inc. (formerly known as Rydberg Technologies LLC) **Reviewed by the UMOR Conflict of Interest Review Committee**	
Project Information	
Title: Quantum Cal Laboratory (QCAL)	**U-M Project ID:** 24-PAF07039
Direct Sponsor: Rydberg Technologies Inc.	**Prime Sponsor:** Department of Defense-Defense Advanced Research Projects Agency
Principal Investigator/Department: Alexander Burgers, EECS – ECE Division	
Project Duration: Four (4) Months	**Funding Support:** $54,800
Purpose: The purpose of this project is to define and design a testbed system for testing, integration, and calibration of atom-based quantum electromagnetic field sensors and measurement devices and key subsystems and components to required atomic, optical, and electronic performance requirements.	
University Employee; University Title; Relationship with Rydberg Technologies Inc. ● Georg Raithel; Professor, Physics; Partial Owner	

Project #10

Subcontract Agreement between the University and Tuebor Energy Inc. **Reviewed by the UMOR Conflict of Interest Review Committee**	
Project Information	
Title: High Throughput Fabrication of Integrated Cathode Assemblies for Lithium-Sulfur Batteries	**U-M Project ID:** 24-PAF07621
Direct Sponsor: Tuebor Energy Inc.	**Prime:** U.S. Department of Energy
Principal Investigator/Department: Nicholas Kotov, Chemical Engineering	
Project Duration: Three (3) Years	**Funding Support:** $1,250,000
Purpose: The purpose of this project is to research and develop scalable aramid nanofiber (ANFs) and ANF-based composite ion conductors.	
University Employee; University Title; Relationship with Tuebor Energy Inc. ● Nicholas Kotov; Professor, Chemical Engineering; Partial Owner ● Ahmet Emre; Research Fellow, Chemical Engineering; Partial Owner	